192 related articles for article (PubMed ID: 27270157)
1. High cost sharing and specialty drug initiation under Medicare Part D: a case study in patients with newly diagnosed chronic myeloid leukemia.
Doshi JA; Li P; Huo H; Pettit AR; Kumar R; Weiss BM; Huntington SF
Am J Manag Care; 2016 Mar; 22(4 Suppl):s78-86. PubMed ID: 27270157
[TBL] [Abstract][Full Text] [Related]
2. Association of high cost sharing and targeted therapy initiation among elderly Medicare patients with metastatic renal cell carcinoma.
Li P; Wong YN; Jahnke J; Pettit AR; Doshi JA
Cancer Med; 2018 Jan; 7(1):75-86. PubMed ID: 29195016
[TBL] [Abstract][Full Text] [Related]
3. Specialty Tier-Level Cost Sharing and Biologic Agent Use in the Medicare Part D Initial Coverage Period Among Beneficiaries With Rheumatoid Arthritis.
Doshi JA; Hu T; Li P; Pettit AR; Yu X; Blum M
Arthritis Care Res (Hoboken); 2016 Nov; 68(11):1624-1630. PubMed ID: 27014854
[TBL] [Abstract][Full Text] [Related]
4. Reducing out-of-pocket cost barriers to specialty drug use under Medicare Part D: addressing the problem of "too much too soon".
Doshi JA; Li P; Pettit AR; Dougherty JS; Flint A; Ladage VP
Am J Manag Care; 2017 Mar; 23(3 Suppl):S39-S45. PubMed ID: 29648739
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
Phuar HL; Begley CE; Chan W; Krause TM
J Manag Care Spec Pharm; 2019 Oct; 25(10):1140-1150. PubMed ID: 31556823
[TBL] [Abstract][Full Text] [Related]
6. How Low-Income Subsidy Recipients Respond to Medicare Part D Cost Sharing.
Stuart B; Hendrick FB; Xu J; Dougherty JS
Health Serv Res; 2017 Jun; 52(3):1185-1206. PubMed ID: 27324201
[TBL] [Abstract][Full Text] [Related]
7. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
[TBL] [Abstract][Full Text] [Related]
8. Health Costs and Outcomes Associated with Medicare Part D Prescription Drug Cost-Sharing in Beneficiaries on Dialysis.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2015 Oct; 21(10):956-64. PubMed ID: 26402394
[TBL] [Abstract][Full Text] [Related]
9. The Effects of Cost Sharing on Adherence to Medications Prescribed for Concurrent Use: Do Definitions Matter?
Sacks NC; Burgess JF; Cabral HJ; McDonnell ME; Pizer SD
J Manag Care Spec Pharm; 2015 Aug; 21(8):678-87. PubMed ID: 26233540
[TBL] [Abstract][Full Text] [Related]
10. Adherence and persistence to prescribed medication therapy among Medicare part D beneficiaries on dialysis: comparisons of benefit type and benefit phase.
Park H; Rascati KL; Lawson KA; Barner JC; Richards KM; Malone DC
J Manag Care Spec Pharm; 2014 Aug; 20(8):862-76. PubMed ID: 25062080
[TBL] [Abstract][Full Text] [Related]
11. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.
Yazdany J; Dudley RA; Chen R; Lin GA; Tseng CW
Arthritis Rheumatol; 2015 Jun; 67(6):1474-80. PubMed ID: 25900105
[TBL] [Abstract][Full Text] [Related]
12. Financial Burden for Patients With Chronic Myeloid Leukemia Enrolled in Medicare Part D Taking Targeted Oral Anticancer Medications.
Shen C; Zhao B; Liu L; Shih YT
J Oncol Pract; 2017 Feb; 13(2):e152-e162. PubMed ID: 28095170
[TBL] [Abstract][Full Text] [Related]
13. The effect of out-of-pocket costs on initiation of disease-modifying therapies among medicare beneficiaries with multiple sclerosis.
Hartung DM; Johnston KA; McGregor JC; Bourdette DN
Mult Scler Relat Disord; 2020 Nov; 46():102554. PubMed ID: 33032059
[TBL] [Abstract][Full Text] [Related]
14. Impact of Cost-Sharing Increases on Continuity of Specialty Drug Use: A Quasi-Experimental Study.
Li P; Hu T; Yu X; Chahin S; Dahodwala N; Blum M; Pettit AR; Doshi JA
Health Serv Res; 2018 Aug; 53 Suppl 1(Suppl Suppl 1):2735-2757. PubMed ID: 28736929
[TBL] [Abstract][Full Text] [Related]
15. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
Dusetzina SB; Winn AN; Abel GA; Huskamp HA; Keating NL
J Clin Oncol; 2014 Feb; 32(4):306-11. PubMed ID: 24366936
[TBL] [Abstract][Full Text] [Related]
16. In-gap discounts in Medicare Part D and specialty drug use.
Jung J; Xu WY; Cheong C
Am J Manag Care; 2017 Sep; 23(9):553-559. PubMed ID: 29087157
[TBL] [Abstract][Full Text] [Related]
17. Impact of ibrutinib and idelalisib on the pharmaceutical cost of treating chronic lymphocytic leukemia at the individual and societal levels.
Shanafelt TD; Borah BJ; Finnes HD; Chaffee KG; Ding W; Leis JF; Chanan-Khan AA; Parikh SA; Slager SL; Kay NE; Call TG
J Oncol Pract; 2015 May; 11(3):252-8. PubMed ID: 25804983
[TBL] [Abstract][Full Text] [Related]
18. Factors Associated With Tyrosine Kinase Inhibitor Initiation and Adherence Among Medicare Beneficiaries With Chronic Myeloid Leukemia.
Winn AN; Keating NL; Dusetzina SB
J Clin Oncol; 2016 Dec; 34(36):4323-4328. PubMed ID: 27998234
[TBL] [Abstract][Full Text] [Related]
19. Myopic and Forward Looking Behavior in Branded Oral Anti-Diabetic Medication Consumption: An Example from Medicare Part D.
Sacks NC; Burgess JF; Cabral HJ; Pizer SD
Health Econ; 2017 Jun; 26(6):753-764. PubMed ID: 27150938
[TBL] [Abstract][Full Text] [Related]
20. Adherence to tyrosine kinase inhibitors among Medicare Part D beneficiaries with chronic myeloid leukemia.
Shen C; Zhao B; Liu L; Shih YT
Cancer; 2018 Jan; 124(2):364-373. PubMed ID: 28976559
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
